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Abstract
 
Fibrin, a product of the blood coagulation cascade, accompanies many type 1 immune re-
sponses, including delayed-type hypersensitivity, autoimmunity, and graft rejection. In those
settings, fibrin is thought to exacerbate inflammation and disease. Here, we evaluate roles for
coagulation during infection with 
 
Toxoplasma gondii
 
, a pathogen whose control requires robust
type 1 immunity. We establish that fibrin prevents infection-stimulated blood loss, thereby per-
forming a protective function that is essential for survival. Remarkably, fibrin does not simply
protect against vascular damage caused directly by the infectious agent, but rather, protects
against hemorrhage evoked by interferon-
 
 
 
, a critical mediator of type 1 immunity. This find-
ing, to our knowledge, is the first to document a beneficial role for coagulation during type 1
immunity, and suggests that fibrin deposition protects host tissue from collateral damage caused
by the immune system as it combats infection.
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Introduction
 
During the coagulation cascade, fibrin is generated by the
action of thrombin on fibrinogen. Although best appreci-
ated for its roles in vascular hemostasis, coagulation leading
to fibrin deposition also frequently accompanies type 1
immune responses, including delayed-type hypersensitiv-
ity (1–3), autoimmunity (4–10), and graft rejection (11–
13). Prior studies indicate that fibrin, and other coagulant
products, can exacerbate inflammation and disease in those
settings (1–16). Coagulation also frequently accompanies
infectious disease, and apparently can exacerbate pathology
in that context as well (16). Indeed, administration of acti-
vated protein C, a natural anticoagulant protein, reduces
septic mortality in humans (17). While these and other
studies have documented pathological roles for coagulation
during immunity and infection, beneficial functions for
immune-associated coagulation have yet to be established.
 
Toxoplasma gondii
 
 is a widely distributed, obligate intra-
cellular, protozoan parasite (18, 19). Natural infection is ac-
quired by ingestion of encysted organisms, which are re-
leased in the digestive tract, invade intestinal tissues, and
then disseminate. In mouse models, 
 
T. gondii
 
 infection elic-
its a robust type 1 immune response, which eradicates most
parasites within 2 wk of infection. Nevertheless, some or-
ganisms escape immune surveillance, encyst, and enter a
dormant state from which they can emerge if immunity
wanes, as frequently occurs in humans suffering from the
acquired immunodeficiency syndrome.
Here, we evaluate roles for fibrin in the context of the
strong type 1 immune response prompted by 
 
T. gondii
 
 in-
fection. In contrast to prior studies of immune-associated
fibrin deposition, we demonstrate that coagulation per-
forms a critical protective function in the setting of 
 
T. gon-
dii
 
 infection by suppressing hemorrhage evoked by IFN-
 
 
 
,
a critical mediator of type 1 immunity. Thus, while coagu-
lant products have the potential to function pathologically,
our data indicate that immune-associated coagulative re-
sponses can also protect host tissue from collateral damage
caused by the immune system as it combats infection.
 
Materials and Methods
 
Mice.
 
6–10-wk-old male mice were used for all experi-
ments. C57BL/6 and IFN-
 
 
 
–deficient mice were purchased
from Taconic and The Jackson Laboratory, respectively. Fibrin-
ogen-deficient mice (reference 20; backcrossed seven genera-
tions to C57BL/6 mice) were generously supplied by Jay Degen
(Children’s Hospital Medical Center, Cincinnati, OH) and
were bred at the Trudeau Institute Animal Breeding Facility.
Animals were housed in a specific pathogen-free facility and
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cared for according to the Trudeau Institute Animal Care and
Use Committee guidelines.
 
Infections. T. gondii
 
 strain ME49 was originally provided by
Jack Remington (Palo Alto Medical Foundation, Palo Alto, CA).
ME49 cysts were obtained from brains of chronically infected
C57BL/6 mice, and infections were initiated by peroral adminis-
tration of 10 cysts in 0.1 ml of diluted brain suspension using a
19-gauge gavage needle. Sham-infected mice received similarly
diluted brain suspensions from uninfected mice. Where indi-
cated, 2 mg/L warfarin (3-(
 
 
 
-acetonylbenzyl)-4-hydroxy-cou-
marin; Sigma-Aldrich) was added to drinking water and replen-
ished every 48 h. The anti–IFN-
 
 
 
 mAb XMG1.2 and control rat
IgG1 mAb HRPN were Protein A–purified from culture super-
natants. Each contained 
 
 
 
1 EU/mg as determined by 
 
Limulus
 
amebocyte lysate assay.
 
Measurements of Immune Parameters.
 
IFN-
 
 
 
 protein levels in
sera were determined by sandwich ELISA (BD Biosciences). Ni-
tric oxide levels in plasma were determined as described (21), ex-
cept that plasma was diluted fourfold in water and filtered (10000
MWCO; Amicon) before analysis. Tissue levels of mRNA en-
coding IFN-
 
 
 
, TNF-
 
 
 
, IL-10, inducible nitric oxide synthase
(iNOS), and the 
 
T. gondii
 
 p30 gene were measured by real-time
PCR (PerkinElmer) and normalized to levels of 
 
 
 
-2-microglob-
ulin (
 
 
 
2m). For 
 
T. gondii
 
, standard curves were prepared by add-
ing known numbers of ME49 tachyzoites (obtained from perito-
neal exudate fluid of 
 
T. gondii
 
–infected IFN-
 
 
 
–deficient mice) to
uninfected liver tissue, and then preparing cDNA. Real-time
PCR primer and probe sequences were previously described
(22), supplied by Daniel Douek (NIH Vaccine Research Center,
Bethesda, MD), or designed using Primer Express software
(PerkinElmer). Except for p30, each primer combination ampli-
fies cDNA, but not genomic DNA. p30-forward TTTC-
CGAAGGCAGTGAGACG, p30-reverse GGATCCGATGC-
CATAGCG, p30-probe TTGCCGCGCCCACACTGATG);
IFN-
 
 
 
-forward CATTGAAAGCCTAGAAAGTCTGAATAAC,
IFN-
 
 
 
-reverse TGGCTCTGCAGGATTTTCATG, IFN-
 
 
 
-probe
TCACCATCCTTTTGCCAGTTCCTCCAG; TNF-
 
 
 
-forward
CATCTTCTCAAAATTCGAGTGACAA, TNF-
 
 
 
-reverse TGG-
GAGTAGACAAGGTACAACCC, TNF-
 
 
 
-probe CACGTC-
GTAGCAAACCACCAAGTGGA; IL-10-forward GAAGAC-
CCTCAGGATGCGG, IL-10-reverse ACCTGCTCCACTG-
CCTTGCT, IL-10-probe TGAGGCGCTGTCATCGATTT-
CTCCC; iNOS-forward CAGCTGGGCTGTACAAACCTTC,
iNOS-reverse CATTGGAAGTGAAGCGTTTCG, iNOS-probe
CGGGCAGCCTGTGAGACCTTTGA; 
 
 
 
2m-forward TGAC-
CGGCTTGTATGCTATC, 
 
 
 
2m-reverse CAGTGTGAGCC-
AGGATATAG, 
 
 
 
2m-probe TATACTCACGCCACCCACC-
GGAGAA.
 
Measurement of Fibrin Levels.
 
Fibrin levels within tissue sam-
ples were quantified essentially as described previously (23, 24).
Tissue was harvested from anticoagulated mice (500 U heparin,
intravenously), weighed, and stored at –70
 
 
 
C. Samples were then
homogenized in 10 mM sodium phosphate (pH 7.5) containing 5
mM EDTA, 100 mM 
 
 
 
-aminocaproic acid, 10 U/ml aprotinin,
10 U/ml heparin, and 2 mM phenylmethanesulfonyl fluoride.
After overnight rocking at 4
 
 
 
C, insoluble fibrin was pelleted
(10,000 
 
g
 
, 10 min), washed (10 mM sodium phosphate, 5 mM
EDTA), extracted twice with 3 M urea at 37
 
 
 
C, and then solubi-
lized in reducing SDS-PAGE buffer at 65
 
 
 
C. Samples were nor-
malized based upon the initial tissue weight. Fibrin levels were
then quantified by Western blotting, using biotinylated anti-
 
 
 
fibrin mAb 350 (2 ng/ml; American Diagnostica, Inc.) fol-
lowed by rabbit anti-biotin (1:20,000; DakoCytomation), anti–
rabbit horseradish peroxidase polymer (1:40; DakoCytomation),
and chemiluminescent detection (Santa Cruz Biotechnology,
Inc.). To generate fibrin for standard curves, purified mouse fi-
brinogen (Sigma-Aldrich) was treated with human thrombin (En-
zyme Research Laboratories).
 
Statistics.
 
Statistical analyses were performed using the pro-
gram Instat 3.0 (GraphPad Software), using either Mann-Whit-
ney or Student’s 
 
t
 
 tests, as appropriate.
 
Results
 
Upon peroral infection with 10 cysts of avirulent strain
ME49 
 
T. gondii
 
, C57BL/6 mice mount a prototypical type
1 immune response, characterized by robust IFN-
 
 
 
 pro-
duction, which soon contains parasite replication (Fig. 1;
references 19 and 25). We found that infection with 
 
T.
gondii
 
 also prompted a transient coagulative response. Fibrin
was never detectable within tissues of uninfected mice.
However, as reported for many other conditions that elicit
type 1 immunity (1–13), we detected markedly elevated
levels of fibrin in 
 
T. gondii
 
–infected mice (Fig. 1). Fibrin
deposition within hepatic and intestinal tissues peaked at
day 8 after infection, correlating kinetically with peaks in
both parasite burdens and hallmarks of type 1 immunity
(Fig. 1, and unpublished data).
To evaluate the function of this infection-stimulated co-
agulative response, we treated mice with warfarin, an orally
available pharmaceutical used clinically for the long-term
anticoagulation of thrombosis-prone humans. Supplement-
ing drinking water with 2 mg/L warfarin did not impair
the growth or survival of uninfected mice, but was clini-
cally effective, as it suppressed 
 
T. gondii
 
–stimulated fibrin
deposition to below the detection limit of our assay (un-
published data). Strikingly, warfarin-treated mice acutely
Figure 1. Fibrin formation ac-
companies  T. gondii infection.
Wild-type C57BL/6 mice were
infected with T. gondii (10 strain
ME49 cysts, peroral). On the in-
dicated days, we measured para-
site burdens within liver tissue
(A), IFN-  protein levels in sera
(B), and fibrin deposition within
liver tissue (C). Data depict the
averages   SD of five mice per
time point. Dashed lines indicate
levels of detection, and open cir-
cles depict points below that
level.  T. gondii infection stimu-
lated significant increases in liver
fibrin deposition (P   0.01),
peaking at day 8 d after infection,
and correlating with peak para-
site burdens and IFN-  levels.T
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succumbed to 
 
T. gondii
 
 infection, dying around the time of
the peak coagulative response of untreated animals (Fig. 2
A). That finding suggested that coagulation might function
protectively during 
 
T. gondii
 
 infection.
To specifically evaluate protective roles for fibrin during
 
T. gondii
 
 infection, we examined gene-targeted fibrinogen-
deficient mice (20), which cannot produce fibrin. We
found that fibrinogen-deficient mice also succumbed
acutely to 
 
T. gondii
 
 infection (Fig. 2 B). As infection
prompted fibrin deposition in normal mice (Fig. 1), and
acute mortality in both warfarin-treated and fibrinogen-
deficient mice (Fig. 2), we conclude that fibrin performs a
critical protective function during 
 
T. gondii
 
 infection.
Fibrin may protect against infection-triggered mortality
via a number of plausible mechanisms. As levels of fibrin
and parasitemia correlated (Fig. 1), we considered the pos-
sibility that coagulation might function to physically limit
parasite dissemination (14). However, parasite numbers
within liver, intestine, Peyer’s patch, spleen, and brain
were not significantly increased in fibrinogen-deficient
mice (Fig. 3, and unpublished data).
We next assessed whether fibrin might function protec-
tively by affecting immunity. Aberrant levels of IL-12,
IFN-
 
 
 
, TNF-
 
 
 
, IL-10, nitric oxide, or neutrophils can im-
pair survival of 
 
T. gondii
 
-infected mice (19). However, us-
ing ELISA, real-time PCR, and/or histologic assays, we
never observed significant differences in levels of those me-
diators when comparing 
 
T. gondii
 
-infected fibrinogen-defi-
cient and littermate control mice (Fig. 3, and unpublished
data). Thus, fibrin probably does not function protectively
during 
 
T. gondii
 
 infection by influencing levels of critical
immune mediators.
In experimental models, acute mortality during 
 
T. gondii
 
infection can result from either a failure to control parasite
numbers, or excessive immunopathology (19). During the
course of our studies we noted exacerbated gross pathology
in liver tissue of 
 
T. gondii
 
–infected fibrinogen-deficient
mice (Fig. 4 B). Microscopic examination revealed intense
infiltration of mixed inflammatory cells and areas of hepa-
tocellular necrosis in livers of 
 
T. gondii
 
–infected control
mice (Fig. 4 C). In fibrinogen-deficient mice, infiltrates
tended to be more diffuse, and necrosis was more extensive
and frequently associated with hemorrhage (Fig. 4 D).
To quantitatively assess whether infection-stimulated fi-
brin formation protects against hemorrhagic events, we
evaluated hematologic parameters in 
 
T. gondii
 
–infected
mice (Fig. 5). In wild-type mice, we observed significant
reductions in hematocrits, red cell numbers, and hemoglo-
bin levels during the course of 
 
T. gondii
 
 infection, first evi-
dent around day 8 after infection and peaking around day
10 (Fig. 5 A, and unpublished data). Compared with con-
trol heterozygous mice, 
 
T. gondii
 
–infected fibrinogen-defi-
cient mice displayed significantly greater reductions in he-
matocrits, red cell counts, and hemoglobin levels at day 8
after infection (all P 
 
 
 
 0.05; Fig. 5 B, and unpublished
data). Treatment of wild-type mice with warfarin similarly
exacerbated infection-associated red cell loss (unpublished
data). Evaluation of peripheral blood smears revealed ele-
vated numbers of reticulocytes, suggesting that red cell loss
likely reflected infection-stimulated hemorrhage, rather
than decreased erythropoiesis. Together, our histologic and
Figure 2. Fibrin functions protectively during T. gondii infection. (A)
Wild-type C57BL/6 mice were infected with T. gondii. Where indicated,
mice were anticoagulated with warfarin. Anticoagulated mice succumbed
to T. gondii infection significantly earlier than did untreated mice (P  
0.01; n   5 mice per group). (B) Fibrinogen-deficient (Fib KO) mice and
littermate control fibrinogen-heterozygous (Fib Het) were infected with
T. gondii. Fibrinogen-deficient mice succumbed to T. gondii infection sig-
nificantly earlier than did littermate control mice (P   0.01; n   5 mice
per group). Similar results to those shown in A and B were independently
replicated in two subsequent experiments.
Figure 3. Mice lacking fibrin exhibit neither increased parasite burdens
nor suppressed anti-parasite immunity. Fibrinogen-deficient (white bars)
and littermate control fibrinogen-heterozygous mice (black bars) were in-
fected with T. gondii. Parasite numbers (p30 mRNA in liver), IFN- 
(protein in sera, mRNA in liver), nitric oxide (nitrite/nitrate in sera), in-
ducible nitric oxide synthase (iNOS, mRNA in liver), IL-10 (mRNA in
liver), and TNF-  (mRNA in liver) were assayed on days 4 and 8 after
infection. There were no significant differences in the levels of any of the
measured parameters. The data shown was compiled from four indepen-
dent experiments. Bars depict average   SD of 8 mice per group (Day 0),
4 mice per group (Day 4), or 14 to 16 mice per group (Day 8).T
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hematologic observations indicate that coagulation protects
against hemorrhage during 
 
T. gondii
 
 infection.
We next assessed how infection evokes a coagulative re-
sponse. 
 
T. gondii
 
 infects all nucleated cells (18), and thus has
the potential to directly damage vascular cells, thereby
causing hemorrhage and activating a coagulative response.
However, parasite-stimulated immunopathology could also
prompt hemorrhage leading to coagulation, as levels of
IFN-
 
 
 
 and its potentially destructive downstream product,
nitric oxide, both peak around the time of the acute death
of coagulation-impaired 
 
T. gondii
 
–infected animals (Fig. 1,
and unpublished data). Notably, IFN-
 
 
 
 also up-regulates
Figure 4. Exacerbated hepatic pathology in T. gondii-infected, fibrin-deficient mice. Representative liver lobes harvested at day 8 after T. gondii infec-
tion of littermate control fibrinogen-heterozygous (A) and fibrinogen-deficient (B) mice. Hemorrhagic foci are evident in livers of T. gondii–infected fi-
brinogen-deficient mice. (C and D) Micrographs (200 ) depicting hematoxylin and eosin stained tissue samples isolated from T. gondii–infected mice.
Note that areas of hepatocellular necrosis, which are characteristic of T. gondii infection in fibrinogen-sufficient mice (arrow in C), are largely replaced by
hemorrhagic pathology in fibrinogen-deficient mice (arrow in D).
Figure 5. Fibrin protects
against infection-stimulated,
IFN- –mediated hemorrhagic
immunopathology. (A) Wild-
type C57BL/6 mice were in-
fected with T. gondii. On the in-
dicated days, blood was collected
and hematocrits, red cell num-
bers (unpublished data), and he-
moglobin levels (unpublished
data) were determined using a
Coulter Counter (Beckman
Coulter). Compared with unin-
fected mice, each of those pa-
rameters were significantly re-
duced by day 10 after infection
(P    0.001; n    5 mice per
group). (B) Fibrinogen-defi-
cient and littermate control het-
erozygous mice were infected
with T. gondii or were sham in-
fected. On day 8 after infection,
hematocrits were significantly reduced in T. gondii–infected control mice (*P   0.02; n   5
mice per group). Compared with infected control mice, T. gondii–infected fibrinogen-defi-
cient mice displayed even greater hematocrit reductions (**P   0.005; n   5 mice per
group). (C) Wild-type C57BL/6 and C57BL/6-backcrossed IFN- –deficient mice were in-
fected with T. gondii. 8 d later, hematocrits were significantly reduced in T. gondii–infected
wild-type control mice (*P   0.005; n   5 mice per group), but not in the IFN- –deficient
mice. (D) Wild-type C57BL/6 received a single injection (1 mg, intraperitoneal) of control
rat IgG1 mAb or anti–IFN-  mAb ( IFN ). The next day, mice were sham infected or in-
fected with T. gondii. 8 d later, hematocrits were significantly reduced in T. gondii–infected
control mAb-treated mice (*P   0.008; n   5 mice per group), but not in the anti-IFN- –treated mice. (E) Fibrinogen-deficient and littermate control
mice received control rat IgG1 mAb or anti-IFN-  mAb (1 mg, intraperitoneal), and were infected with T. gondii the following day. Hematocrits were
measured at day 8 after infection. In both sets of mice, anti-IFN-  mAb treatment significantly protected against hematocrit reductions (*P   0.01; n  
4 mice per group). Notably, the hematocrits of anti-IFN-  mAb-treated fibrinogen-deficient and littermate control mice were not significantly differ-
ent. Similar results to those shown were replicated in two (A) or more (B–E) independent experiments.T
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cellular expression of procoagulant molecules (26–28),
thereby potentially amplifying fibrin production.
To decisively evaluate roles for IFN-  in T. gondii–stimu-
lated hemorrhagic pathology, we infected gene-targeted
IFN- –deficient mice. Prior studies established that IFN- 
is a major mediator of resistance to T. gondii, as its neutral-
ization leads to increased parasite burdens and acute mortal-
ity (25). Indeed, compared with wild-type mice infected in
parallel, we found that T. gondii parasite numbers were ele-
vated more than 1,000-fold in IFN- –deficient mice at day
8 after infection (P   0.008; n   5; wild-type 77   36 par-
asites/mg liver tissue, IFN- –deficient   79,000   52,000
parasites/mg liver tissue). Nevertheless, hematocrits, red cell
counts, and hemoglobin levels were not significantly re-
duced in T. gondii–infected IFN- –deficient mice (Fig. 5 C,
and unpublished data). We observed similar results upon de-
pletion of IFN-  in wild-type C57BL/6 mice using a spe-
cific neutralizing mAb (Fig. 5 D). As parasite burdens were
elevated, but red cell loss was not, we conclude that parasites
do not directly cause significant hemorrhage. Rather, our
data suggest that fibrin functions to suppress hemorrhagic
pathology caused by IFN- , a product of type 1 immunity.
To formally establish that fibrin functions to suppress
IFN- –stimulated hemorrhagic pathology, we evaluated
IFN- –depleted,  T. gondii–infected, fibrinogen-deficient
mice. We found that neutralization of IFN-  in fibrinogen-
deficient mice suppressed the T. gondii–stimulated gross
liver pathology (unpublished data) and hematocrit reduc-
tions (Fig. 5 E; P   0.01; n   4). Importantly, hematocrits
in IFN- –depleted, T. gondii–infected, fibrinogen-deficient,
and littermate control mice were not significantly different,
establishing that the exacerbated hemorrhagic pathology
observed in fibrinogen-deficient mice, like the lesser pa-
thology observed in wild-type mice, is caused by IFN- .
Numerous prior studies concluded that immune-associ-
ated fibrin deposition exacerbates inflammation and pathol-
ogy. Studies using factors isolated from snake venoms that
transiently generate a fibrinogen-deficient state suggested
pathological roles for fibrin in animals models of glomeru-
lonephritis (4), arthritis (7), encephalomyelitis (9, 10), and
transplant rejection (12). Studies using mice with impaired
fibrin degrading capacities (i.e., gene-targeted plasmino-
gen- or plasminogen activator-deficient mice) confirmed
such pathological roles for fibrin during glomerulonephritis
and arthritis (6–8). Studies using fibrinogen-deficient mice
revealed pathological roles for fibrin(ogen) during athero-
sclerosis (29), and demonstrated that fibrin can up-regulate
expression of inflammatory cytokines and chemokines in
vivo (30). Finally, studies using anticoagulated or congeni-
tally fibrinogen-deficient subjects established that fibrin also
has inflammatory properties in humans (2, 3).
In contrast to those prior reports, our studies demonstrate
that coagulation can also function protectively during im-
munity. Specifically, we found that fibrin can prevent in-
fection-stimulated blood loss, thereby performing a protec-
tive function that is essential for survival. Remarkably,
fibrin does not simply protect against vascular damage
caused directly by the infectious agent, but rather, protects
against hemorrhage evoked by IFN- , a critical mediator of
type 1 immunity. Notably, IFN-  also stimulates expres-
sion of genes that favor and/or stabilize fibrin deposition
(26–28), suggesting that type 1 immunity may have evolved
means to locally up-regulate coagulant activity, thereby
preemptively protecting against its own destructive power.
Our observations indicate that the pathological potential
of immune-associated coagulation is counter-balanced by a
critical protective function. Such findings help to explain
why type 1 immunity frequently elicits fibrin deposition
(1–13), and suggest that clinicians should be cautious in as-
cribing pathological assessments to immune-associated fi-
brin deposits. While the inflammatory activities of fibrin
and other coagulant products may function pathologically
in certain contexts (1–16), immune-associated coagulative
responses can also function beneficially, by protecting
against immunopathology.
Notably, our data do not exclude the possibility that fi-
brin may also function protectively through direct effects
on immunity and/or inflammation. In comparison to litter-
mate control mice, there were no significant differences in
pathogen dissemination or levels of immune mediators in
T. gondii–infected fibrinogen-deficient mice (Fig. 3). How-
ever, the robust type 1 immune response that accompanies
T. gondii infection may have masked immune-related im-
pacts of fibrin-deficiency. Indeed, while own prior work
demonstrated that thrombin can stimulate fibrin-dependent
secretion of inflammatory cytokines/chemokines in vivo
(30), subsequent studies found that endotoxin- or T cell–
stimulated secretion of those same cytokines/chemokines is
fibrin-independent (unpublished data). Thus, we suspect
that infection-stimulated immunity may well mask fibrin’s
inflammatory activities during T. gondii infection.
Our data suggest that fibrin-unrelated coagulation defi-
ciencies, whether genetic or pharmacologic, may also exac-
erbate immunopathology. As such, we are now exploring
the generality of our findings. We are also working to de-
fine precisely how IFN-  evokes pathology necessitating a
protective coagulative response. We anticipate that those
studies may suggest novel therapies for pathologies charac-
terized by extensive fibrin deposition, including transplan-
tation and many forms of autoimmunity, and may also
impact treatments for the numerous virulent human patho-
gens that elicit deleterious coagulative and/or hemorrhagic
responses.
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